Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Increased to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Kiniksa (NASDAQ:KNSA) from "hold" to strong-buy, joining several brokers that raised target prices (examples: Jefferies $71, Canaccord $64, Citi $60) and leaving a MarketBeat average rating of "Moderate Buy" with an average target near $60.86.
• Kiniksa beat Q1 expectations with $0.27 EPS vs. $0.18 consensus and $214.3M revenue (+55% YoY), and management raised FY‑2026 revenue guidance while product momentum and an expected KPL‑387 Phase‑2 readout in 2H‑2026 offer near‑term catalysts.
• Significant insider selling occurred (CEO Sanj K. Patel and others sold large blocks under 10b5‑1 plans), with insiders owning ~53% of shares—heavy sales may weigh on sentiment despite being pre‑arranged.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research note issued on Monday.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 29th. Canaccord Genuity Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a "buy" rating in a research report on Wednesday, April 29th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 29th. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a "buy" rating in a research report on Tuesday, April 28th. Finally, Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $60.86.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $55.27 on Monday. The firm's 50-day moving average price is $46.40 and its 200-day moving average price is $43.20. Kiniksa Pharmaceuticals International has a 1-year low of $24.85 and a 1-year high of $55.28. The firm has a market capitalization of $4.23 billion, a P/E ratio of 61.41 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The business's quarterly revenue was up 55.5% compared to the same quarter last year. Equities research analysts forecast that Kiniksa Pharmaceuticals International will post 1.22 EPS for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares of the company's stock, valued at approximately $2,623,481.30. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the company's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares of the company's stock, valued at $1,280,146.42. The trade was a 19.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 630,652 shares of company stock valued at $32,490,737. 53.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. Qube Research & Technologies Ltd boosted its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after acquiring an additional 653,236 shares during the last quarter. Rubric Capital Management LP boosted its stake in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock valued at $108,184,000 after acquiring an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company's stock valued at $18,192,000 after acquiring an additional 447,536 shares during the last quarter. Spruce Street Capital LP purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $17,943,000. Finally, SG Americas Securities LLC boosted its stake in Kiniksa Pharmaceuticals International by 288.6% in the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company's stock valued at $22,333,000 after acquiring an additional 402,078 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.